Skip to Main Content

Biogen

Biogen Inc., of Cambridge, Mass., is a multinational biotechnology giant offering products related to depression, Alzheimer’s disease, multiple sclerosis, hemophilia and leukemia. Here’s the latest Biogen news.

Latest

Health tech Mario Aguilar

STAT Plus: Biogen turns to telehealth company to boost its postpartum depression drug

Biotech Adam Feuerstein

STAT Plus: Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

Biotech Elaine Chen and Adam Feuerstein

STAT Plus: Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the third quarter: 19 stock-moving events to watch

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

The Readout Elaine Chen

STAT Plus: Looking for signs of growth in Biogen’s earnings

Exclusive Bob Herman and Rachel Cohrs Zhang

STAT Plus: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025

All Coverage

Biotech Adam Feuerstein

STAT Plus: The biotech scoreboard for the second quarter: 32 stock-moving events to watch

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

advertisement

Biotech Damian Garde

STAT Plus: Years after a polarizing approval, Biogen walks away from Aduhelm

Exclusive Mario Aguilar and Matthew Herper

STAT Plus: Biogen shutters digital health group, nixes Apple study, as part of cost cuts

Biotech Brittany Trang

STAT Plus: FDA approves Sage Therapeutics’ rapid-acting medication for postpartum depression but not major depression

Biotech Andrew Joseph and Adam Feuerstein

STAT Plus: Biogen to acquire Reata Pharmaceuticals in $7 billion deal

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Biogen’s sticky situation, Wegovy’s risks, & biotech insider trading

Biotech Matthew Herper and Damian Garde

STAT Plus: Biogen says it will cut costs by $700 million, slash 1,000 jobs

Health tech Brittany Trang

STAT Plus: As Alzheimer’s drugs hit the market, the race for early detection blood tests heats up

Biotech Damian Garde and Adam Feuerstein

STAT Plus: Shareholders elect director’s romantic partner to Biogen’s board

Politics Rachel Cohrs Zhang

STAT Plus: Medicare puts out new details for covering the Alzheimer’s drug Leqembi, as the health system readies for potential approval

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Biogen’s messy board, Laronde’s data problem, & the downside of a boom

Biotech Damian Garde and Adam Feuerstein

STAT Plus: Biogen’s boardroom scandal saddles CEO with first crisis

Exclusive Damian Garde and Adam Feuerstein

STAT Plus: Biotech executive nominated to Biogen board is mother of director’s child, records show

Biotech Adam Feuerstein and Damian Garde

STAT Plus: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease

Biotech Allison DeAngelis

STAT Plus: Biogen board and C-suite are in step as they eye M&A opportunities, new CEO says

Pharmalot Ed Silverman

STAT Plus: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel